- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Living Cell Technologies Group 1 Patients Successfully Treated in Parkinson's Trial
Living Cell Technologies Limited has completed treatment of all six patients in group 1 of the Phase IIb clinical trial of NTCELL® for Parkinson’s disease, at Auckland City Hospital.
Living Cell Technologies Limited has completed treatment of all six patients in group 1 of the Phase IIb clinical trial of NTCELL® for Parkinson’s disease, at Auckland City Hospital. Four patients had 40 NTCELL microcapsules implanted into the putamen on each side of their brain, and two patients had sham surgery with no NTCELL implanted. To date there are no safety issues in any of the six patients.
The company is blind to the results until 26 weeks after completion of
the trial, at which point the patients who received the placebo will
receive the optimal dose of NTCELL.
The next step is the Data Safety Monitoring Board reviewing the
patients’ results and giving approval to treat the six patients in group
2 with the next dose of NTCELL (80 microcapsules implanted into the
putamen on each side of their brain).
Principal Investigator Dr Barry Snow presented data from the earlier
Phase I/IIa clinical trial to prospective patients and their partners
and supporters at meetings organised by Parkinson’s New Zealand. These
meetings were oversubscribed and have assisted patient recruitment for
the clinical trial.
Auckland City Hospital has invested in additional equipment and arranged
extra surgical sessions dedicated to treating multiple patients in the
clinical trial. These measures will accelerate trial progress.
The company plans to complete group 2 by the end of 2016 and group 3 by
the end of February 2017.
The Phase IIb trial aims to confirm the most effective dose of NTCELL,
define any placebo component of the response and further identify the
initial target Parkinson’s disease patient sub group. If the trial is
successful, the company will apply for provisional consent to treat
paying patients in New Zealand in Q4 2017.
For further information: www.lctglobal.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.